Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754498 | 0.81 | HRH3 (0.33) | LMNAKMT2AHRH3ALDH1A1TSHR | |
| SCHEMBL25754502 | 0.78 | LMNA (0.35) | LMNAMEN1KMT2AL3MBTL1HRH3 | |
| SCHEMBL25754525 | 0.73 | HRH3 (0.32) | LMNAHRH3ALDH1A1 | |
| Hydroxyamine SCHEMBL1454400 | 0.72 | L3MBTL1 (0.50) | LMNAMEN1KMT2AL3MBTL1HRH3 | |
| SCHEMBL10510078 | 0.69 | HRH3 (0.49) | LMNAMEN1KMT2AL3MBTL1HRH3 | |
| SCHEMBL1455583 | 0.69 | HRH3 (0.49) | LMNAMEN1KMT2AL3MBTL1HRH3 | |
| SCHEMBL25754390 | 0.69 | LMNA (0.35) | LMNAL3MBTL1HRH3MAPTANPEP | |
| SCHEMBL25754249 | 0.69 | HRH3 (0.38) | MEN1KMT2AHRH3ALDH1A1MAPT | |
| SCHEMBL25754591 | 0.69 | HRH3 (0.38) | MEN1KMT2AHRH3ALDH1A1MAPT | |
| SCHEMBL8553534 | 0.68 | HRH3 (0.44) | LMNAL3MBTL1HRH3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | LMNA 1517/4885MEN1 940/4885KMT2A 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.